SCHEMBL7039862

SCHEMBL7039862

Cc1ccc(-c2ccc(CNC(=O)c3cc(N(C=O)c4ccccc4-c4ccc(C)cc4)cn3C)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
TP53 P04637 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
AKR1C4 P17516 3/20 0.41
AKR1C3 P42330 3/20 0.41
AKR1C2 P52895 2/20 0.41
MMP1 P03956 2/20 0.40
MMP7 P09237 2/20 0.40
MMP9 P14780 2/20 0.40
MMP8 P22894 2/20 0.40
MMP13 P45452 2/20 0.40
MMP3 P08254 1/20 0.40
MMP12 P39900 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7039775 0.89 HDAC1 (0.42) AKR1C3BRD4HDAC1PPARG
SCHEMBL7037179 0.84 PPARG (0.45) AKR1C3BRD4HDAC1PPARG
SCHEMBL7039279 0.84 HDAC1 (0.38) TP53POLBL3MBTL1AKR1C3GAA
SCHEMBL7036335 0.83 HDAC1 (0.41) MEN1KMT2AGAABRD4HDAC1
SCHEMBL7041100 0.83 GSK3B (0.46) MMP13BRD4HDAC1PPARG
SCHEMBL7035890 0.77 MAPK14 (0.39) LMNAPOLBGAAGFERBRD4
SCHEMBL7041745 0.76 KMT2A (0.46) LMNAPOLBMEN1KMT2AALDH1A1
SCHEMBL7039859 0.75 CHRNB2 (0.47) LMNATP53RXFP1POLBL3MBTL1
SCHEMBL7039230 0.74 CHRNB2 (0.51) LMNATP53POLBL3MBTL1MEN1
SCHEMBL7039289 0.73 HDAC8 (0.39) TP53POLBL3MBTL1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals APOB, LIPC, MTPN LMNA 1024/4885TP53 3704/4885RXFP1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.